Background-The pro-mutagenic lesion O 6 -methyldeoxyguanosine (O 6 -MedG), a marker of exposure to many N-nitroso compounds (NOC), can be detected in normal and tumour DNA isolated from colorectal tissue. The biological significance of this exposure is, as yet, unknown but in situ NOC formation is bacterially catalysed suggesting that NOC formation and potentially DNA alkylation will vary throughout the large bowel. Colon cancer is one of the most common cancers in the developed world and colon carcinogenesis is a multistep process involving both genetic and environmental factors.
Colon cancer is one of the most common cancers in the developed world and colon carcinogenesis is a multistep process involving both genetic and environmental factors. 1 Major advances have resulted in the identification of cancer susceptibility genes and in delineating the genetic changes that accumulate during induction of sporadic colon cancers. [2] [3] [4] In contrast, our knowledge of the environmental factors involved is still relatively limited. Numerous epidemiological studies indicate that dietary factors can modify the risk of colon cancer. 5 For example, vegetable consumption and fibre intake (possibly by reducing the formation of carcinogens or inhibiting cell replication) are inversely associated with risk, whereas meat protein and fat are consistently and positively associated with risk, possibly by being a source of chemical carcinogens. 5 The link between meat protein intake and colorectal cancer risk is usually considered to arise through consumption of heterocyclic amines. 6 However, intake of meat protein may also increase the formation of N-nitroso compounds (NOC) in the human colon. 7 We have previously shown, in two separate studies, that the pro-mutagenic lesion O 6 -methyldeoxyguanosine (O 6 -MedG), a marker of exposure to many NOC, can be detected in normal and tumour DNA isolated from individuals with colorectal cancer. 8 9 As NOC formation is bacterially catalysed, 10 11 NOC formation within the large bowel will vary and this may alter O 6 -MedG levels throughout the large bowel. Hence we have quantified O 6 -MedG levels in a cross sectional study of patients with colorectal tumours to examine if DNA alkylation varies throughout the large bowel: previously, we reported on the association of K-ras mutations and the frequency of DNA alkylation in this population. 
Methods

SUBJECTS
Paired normal (macroscopically normal tissue taken ∼5 cm from the tumour edge) and tumour tissues were taken from 62 individuals (30 men and 32 women: median age 73 years) presenting with colorectal tumours at hospitals within the Manchester area. Sixteen of these individuals had proximal colon tumours (tumours of the caecum (n=13), transverse colon (n=2), and hepatic flexure (n=1)), 21 had sigmoid colon tumours, and 25 rectal tumours. There were no significant age or sex diVerences between these groups (data not shown). (table 1) .
Results
In the proximal colon, the alkylation frequency in tumour DNA samples (60%) was higher than that in DNA from normal tissue (25%; p =0.11; table 1) and O 6 -MedG levels in tumour DNA were higher than levels in normal DNA (p<0.05, Wilcoxon matched pairs test). In contrast, there were no diVerences between the alkylation frequency and O 6 -MedG levels in normal and tumour DNA from individuals with sigmoid colon or rectal tumours (table 1) .
In those individuals with O 6 -MedG in both normal and tumour DNA, there was no association between levels of O 6 -MedG in normal DNA and those in tumour DNA from the same individual (data not shown). The ratio of O 6 -MedG in normal DNA to that in tumour DNA was 0.53 in the caecum (n=2), 0.96 in the sigmoid colon (n=4), and 1.95 in the rectum (n=10; p=0.19 for diVerences in the ratios using the Kruskal-Wallis test). Twenty individuals had no detectable O 6 -MedG levels in either normal (n) or tumour (t) DNA (n−t−) whereas 16 individuals had O 6 -MedG present in both DNA samples (n+t+). In a further eight individuals, O 6 -MedG was detected only in normal DNA (n+t−) whereas in 14 individuals O 6 -MedG was detected only in tumour DNA (n−t+). The variation in proportions of n-t-, n+t-, n-t+, and n+t+ individuals with tumour site is shown in fig 2. The proportion of individuals with both samples alkylated increased from 13% in the proximal colon to 21% in the sigmoid colon to 42% in the rectum (p=0.05, 2 test for trend).
Discussion
Previous studies have shown that DNA alkylation is a common event in colorectal tissue but the source of exposure to the methylating agents remains to be identified. These results confirm our previous study in a separate population of patients with colorectal disease, 8 in demonstrating that colorectal DNA, obtained from individuals with malignant colorectal disease, contains detectable amounts of the pro-mutagenic and pro-carcinogenic lesion O 6 -MedG. Furthermore, evidence from the current study indicates that O 6 -MedG levels vary within the large bowel as (i) DNA alkylation was higher in normal tissue from the sigmoid colon and rectum than in the proximal colon, (ii) only 13% of paired normal and tumour DNA samples obtained from the proximal colon were both alkylated compared with 21% in the sigmoid colon and 42% in the rectum, and (iii) O 6 -MedG levels in tumour DNA from the proximal colon (but not the sigmoid colon or rectum) were greater than those in normal DNA.
A number of diVerent mechanisms acting either singly or in combination could account for this variation in O 6 -MedG levels within the colon and rectum. Firstly, the methylating agent may arise from bacterial catalysed N-nitrosation reactions within the large bowel as it is known that (i) bacterial composition and their metabolic capacity varies significantly within the intestinal tract 14 15 and (ii) the lumen of the large bowel contains high concentrations of nitrogen containing compounds 16 and is therefore a site for nitrosation reactions, presumably catalysed by resident bacterial flora. 10 This has been shown to lead to the formation of large quantities of apparent total N-nitroso compounds but not volatile nitrosamines such as N-nitrosodimethylamine. 7 10 11 It is possible therefore, that these reactions could lead to the in situ formation of a methylating agent within the lower portion of the bowel and hence to increased DNA damage at the sites of formation.
Alternatively, diVerences in the formation of methylating agents within the colon and rectum may arise through diVerential expression of carcinogen metabolising enzymes, 17 perhaps through dietary induced variations in gene expression. 18 Such diVerences may lead to increased formation or detoxification of the methylating agent(s), thereby leading to diVerences in adduct levels. In addition, although differences in the levels of O 6 -alkylguanine DNA alkyltransferase within the colon could also account for variations in O 6 -medG levels, no association between levels of the repair protein and adduct was observed (data not shown), suggesting that in this case changes in repair capacity were not an important factor in explaining the observed diVerential. Finally, the increased alkylation in the lower bowel may result simply from increased time of contact (and not formation) with lumenally borne genotoxic agents such as N-nitrosated bile acids. 19 Our results also tend to indicate that factors aVecting DNA alkylation in tumour tissue vary from those aVecting alkylation in normal tissue. There was no gradient in O 6 -MedG levels in tumour DNA from the proximal colon to the rectum. Such discrepancies may result from differences in carcinogen metabolising enzymes between normal and tumour tissue. [20] [21] [22] At one The biological significance of these observed levels of DNA alkylation in the human colon remains to be determined, particularly as concentrations and frequencies of alkylation are similar in this population to those observed in other tissues from populations with diVering and greater cancer risks. However, it is of interest that O 6 -MedG levels were highest in the sigmoid colon and rectum-that is, the sites where most sporadic large bowel tumours occur. 1 Such an association, however, may be tenuous, particularly as we measured the adduct in a mixed population of cells from diVerent locations in diVerent individuals and also, these individuals had a tumour which potentially may aVect the biomarker. Furthermore, the adduct measurement probably reflects recent/current exposure which may bear no relationship to exposure in the aetiologically relevant time frame. However, in experimental studies, colon tumours induced by dimethylhydrazine in rats occurred in the distal portion of the colon, precisely in the region where DNA adducts are highest (Jackson et al, unpublished work).
There is further evidence to suggest that methylating agent exposure may be important. Vegetable and micronutrient intake, which reduce the risk of large bowel cancer, also reduce endogenous NOC formation and NOC tumorigenicity. 23 24 Large bowel tumours contain mutational events (for example, K-ras GC-AT transitions and mismatch repair defects [25] [26] [27] [28] [29] ) that have been shown to occur in vitro and in vivo following exposure to alkylating agents. [30] [31] [32] Moreover, we have found evidence to indicate that the DNA repair protein, O 6 -alkylguanine DNA alkyltransferase, provides protection against the mutagenic eVects of alkylating agents in the lower intestinal tract as individuals with low O 6 -alkylguanine DNA alkyltransferase activity were at increased risk of having a GC-AT transition K-ras mutation but not a transversion mutation. 33 This result is entirely consistent with the known action of the repair protein in (i) removing O 6 -MedG lesions from DNA 34 and (ii) reducing the frequency of K-ras GC-AT transitions in an experimental model of large bowel cancer, 35 thereby suggesting a role for methylating agents in the aetiology of these cancers.
